Organon Moves Into Branded Dermatology With Dermavant Takeout

 
• By Joseph Haas

Organon will pay $175m up front for Roivant subsidiary Dermavant and its topical therapy for psoriasis Vtama. The acquirer is betting on growth from adding atopic dermatitis to Vtama’s label.

Acquired
Organon will move into branded dermatology with buyout of Dermavant • Source: Shutterstock

More from Strategy

More from Business